GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (OTCPK:VCNX) » Definitions » Equity-to-Asset

VCNX (Vaccinex) Equity-to-Asset : -0.27 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vaccinex's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-1.32 Mil. Vaccinex's Total Assets for the quarter that ended in Sep. 2024 was $4.85 Mil. Therefore, Vaccinex's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was -0.27.

The historical rank and industry rank for Vaccinex's Equity-to-Asset or its related term are showing as below:

VCNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.53   Med: -0.64   Max: 0.89
Current: -0.27

During the past 8 years, the highest Equity to Asset Ratio of Vaccinex was 0.89. The lowest was -9.53. And the median was -0.64.

VCNX's Equity-to-Asset is ranked worse than
87.87% of 1509 companies
in the Biotechnology industry
Industry Median: 0.67 vs VCNX: -0.27

Vaccinex Equity-to-Asset Historical Data

The historical data trend for Vaccinex's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Equity-to-Asset Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -5.70 -2.27 0.75 0.65 -0.64

Vaccinex Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -0.64 0.36 -1.21 -0.27

Competitive Comparison of Vaccinex's Equity-to-Asset

For the Biotechnology subindustry, Vaccinex's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaccinex's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Vaccinex's Equity-to-Asset falls into.



Vaccinex Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Vaccinex's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.311/3.631
=-0.64

Vaccinex's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=-1.321/4.854
=-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaccinex  (OTCPK:VCNX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Vaccinex Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Vaccinex's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaccinex Business Description

Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Executives
Albert Friedberg director, 10 percent owner
Van Strydonck, Gerald E. director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer director, 10 percent owner, officer: President and CEO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Jacob B. Frieberg director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans officer: Chief Operating Officer C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala officer: Chief Commercial Officer 1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk director 1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc. director 1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard officer: SVP, Development 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith officer: SVP, Research & CSO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins officer: SVP & Chief Operating Officer 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620

Vaccinex Headlines

From GuruFocus

Vaccinex, Inc. Announces Reverse Stock Split

By Marketwired 09-22-2023